AU2015277554B2 - Transdermal formulations of pergolide and uses thereof - Google Patents

Transdermal formulations of pergolide and uses thereof Download PDF

Info

Publication number
AU2015277554B2
AU2015277554B2 AU2015277554A AU2015277554A AU2015277554B2 AU 2015277554 B2 AU2015277554 B2 AU 2015277554B2 AU 2015277554 A AU2015277554 A AU 2015277554A AU 2015277554 A AU2015277554 A AU 2015277554A AU 2015277554 B2 AU2015277554 B2 AU 2015277554B2
Authority
AU
Australia
Prior art keywords
pergolide
formulation
salt
dimethyl sulfoxide
benzyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015277554A
Other versions
AU2015277554C1 (en
AU2015277554A1 (en
Inventor
Sara Elizabeth CRAWLEY
Amy Louise Marr
Jane Granville Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Audevard
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2015277554A1 publication Critical patent/AU2015277554A1/en
Application granted granted Critical
Publication of AU2015277554B2 publication Critical patent/AU2015277554B2/en
Assigned to ELANCO US INC. reassignment ELANCO US INC. Request for Assignment Assignors: ELI LILLY AND COMPANY
Publication of AU2015277554C1 publication Critical patent/AU2015277554C1/en
Assigned to AUDEVARD reassignment AUDEVARD Request for Assignment Assignors: ELANCO US INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Abstract

This invention provides transdermal non-patch pergolide formulations useful for the treatment of disease in an equine. The invention also provides methods for treating a disease in an equine by administering a formulation of the invention to an equine.

Description

The invention also provides methods for treating a disease in an equine by administering a formulation of the invention to an equine.
WO 2015/195448
PCT/US2015/035237
-1TRANSDERMAL FORMULATIONS OF PERGOLIDE AND USES THEREOF
Equine Cushing’s Disease (ECD), also known as Pituitary Pars Intermedia Dysfunction or PPID, is one of the most common hormonal disorders that occurs in equines. Hypertrophy and hyperplasia of the pituitary pars intermedia are often observed in ECD. The resulting clinical signs in equines may include hirsutism, polydipsia, polyuria, hyperhydrosis, protein catabolism (decreased muscle mass), episodes of laminitis, glucose intolerance and insulin refractoriness, suppression of the immune system, and general lethargy. ECD is a progressive disease mainly affecting aged equines (>15 years), but has been recognized in individuals as young as 7 years. The etiology and pathogenesis of ECD are not completely understood but are thought to derive from degeneration of the periventricular hypophyseal dopaminergic neurons and concomitant loss of dopaminergic inhibition of POMC-derived peptides. Prognosis tends to be associated with the prevalence of laminitis in the equine as the effects of this clinical sign are usually most severe.
Pergolide is an ergoline derivative which exhibits potent dopaminergic agonist activity at both I) j and ID dopamine receptors and also decreases plasma prolactin concentrations. The compound is useful in treating physiological manifestations associated with hyperprolactinemia. Pergolide is considered to be a standard of care for the treatment of ECD and is typically administered orally to equines. An oral tablet for daily administration is available in some countries. However, the tablet can be difficult to administer orally due to the tablet’s poor palatability in equines, the large size of equines, and the efforts required to force swallowing by the equines, which are compounded by the need to dose the oral tablet daily. Various oral suspensions and powders of pergolide can be compounded by a pharmacist for veterinary use. However, limitations of compounded pergolide formulated for oral dosing include the variation in dosages due to fluctuations in compounding techniques, the poor stability of the formulations, the lack of consistent potency of the formulations, and the potential difficulty in administering the compounded formulations to equines.
Various methods to deliver pergolide to equines have been attempted in order to overcome limitations of oral administration. For example, methods of transdermal application such as patches have potential advantages over oral administration, including
I I:\rbr\Intcrwovcn\NRPortbl\DCC\RBR\16019483_ I .docx-17/11 '2017
2015277554 17 Nov 2017
-2non-invasive dosing, avoidance of the gastrointestinal tract, lack of first pass metabolism, steady, continuous drug delivery rather than a peak and trough phenomenon, potential reduction of side effects by elimination of peaks, possible reduction of lack of effectiveness due to elimination of troughs, and reduced dose frequency for convenience and increased compliance. Transdermal delivery of pergolide in a patch formulation has been evaluated in various animals, including humans and rats. However, the use of a transdermal patch to deliver pergolide to equines introduces additional shortcomings, including the potential absence or non-reproducibility of systemic pergolide exposure in equines, the possibility of damage to patches applied to equines, and the possibility of consumption of patches applied to equines and subsequent toxicity to the equines following consumption.
Investigation into non-patch transdermal formulations for equines has also encountered problems. Attempts at employing transdermal solutions as described generally in the art have resulted in plasma levels of pergolide which are below expected therapeutic values. One issue with the art's non-patch transdermal formulations is that the amount of pergolide, or a salt thereof, which is able to be solublized is, somewhat surprisingly, lower than what is needed to obtain therapeutic plasma concentrations.
Therefore, there exists a need for pergolide formulations which overcome some or all of the limitations of orally, patch, or other transdermal (non-patch) delivered pergolide in order to benefit treatment of equines in veterinary medicine. Accordingly, the present invention provides formulations of pergolide, or a salt thereof, which exhibits desirable properties and provides related advantages for treatment of diseases in equines.
The present invention demonstrates that the dermal barrier to drug permeation can be overcome in equines by using certain transdermal (non-patch) formulations having a sufficient amount of pergolide, or a salt thereof, solubilized therein. Through what is believed to be deposition of pergolide in the stratum corneum of an equine followed by prolonged systemic absorption, the present invention overcomes the limitations of pergolide administered in an oral formulation, a transdermal patch formulation, or other transdermal (non-patch) formulations.
Accordingly, in one embodiment, the invention provides a transdermal non-patch formulation for use in the treatment of Equine Cushing's Disease in an equine comprising
H:\rbr\Intcrwovcn\N RPortbl\DCC\RBR\l6427242_l.docx-7/02/20l8
2015277554 07 Feb 2018
-3 pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable Cs-Cio polyglycolized glyceride, wherein the pergolide or salt thereof is comprised in said solvent system at a solubility of 5 mg/ml or higher.
The invention also provides a method for treating Equine Cushing's Disease in an equine comprising transdermally administering to an equine in need thereof a transdermal non-patch formulation, the formulation comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, Nmethylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable C8-C10 polyglycolized glyceride, wherein the pergolide or salt thereof is comprised in said solvent system at a solubility of 5 mg/ml or higher.
The invention also provides use of a transdermal non-patch formulation in the preparation of a medicament for treating Equine Cushing’s Disease, the formulation comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable C8-C10 polyglycolized glyceride, wherein the pergolide or salt thereof is comprised in said solvent system at a solubility of 5 mg/ml or higher.
As used herein, the term “equine” refers to any member of the horse family, including for example horses, ponies, miniature horses, miniature ponies, donkeys, mules, and zebras. The methods according to the present invention utilize a transdermal administration. As used herein, the term “transdermal” has its ordinary meaning in the art and refers to passage of an agent across at least one skin layer of an equine. As used herein, the term “disease” refers to any disorder, pathology, or condition in equines
H:\rbr\Intcrwovcn\N RPortbl\DCC\RBR\l6427242_l.doc.v7/02/20l8
2015277554 07 Feb 2018
- 3a capable of being treated with pergolide or a salt thereof. In one embodiment, the disease is Equine Cushing’s Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID).
One or more embodiments of the present invention provide one or more advantages. First, the formulations of the invention can be administered to equines at a lower dosing frequency compared to orally-administered pergolide. For example, the dosing can be every other day, or once every three, four, five, six, or seven days. Second, the present invention has an advantageous ease of administration in equines compared to administration of oral formulations of pergolide. Third, the present invention can be formulated in a more uniform solution that is not subject to the widely fluctuating concentrations and formulations of pergolide oral solutions that result from non-uniform solution compounding by a variety of pharmacists. Fourth, use of the present invention provides advantages compared to pergolide administered to equines in a patch formulation. For example, the present invention provides for pergolide administration in a formulation that is not easily damaged or consumed by equines compared to pergolide administered to equines in a patch formulation. Moreover, because the present invention is a transdermal non-patch formulation and not a device, the invention does not require the maintenance of skin contact in equines to maintain appropriate pergolide absorption. The formulations of the invention also provide for a therapeutic concentration of pergolide in the equine's plasma.
The formulations of the present invention comprise pergolide or a salt thereof.
Pergolide is also known by chemical names such as D-6-n-propyl-83methylmercaptomethylergoline, or (83)-8-[(Methylthio)methyl]-6-propylergoline. The chemical structure of pergolide is:
WO 2015/195448
PCT/US2015/035237
Figure AU2015277554B2_D0001
As used herein, the pergolide includes pergolide and the pharmaceutically acceptable salts of pergolide. Such salts include the pharmaceutically acceptable salts listed in HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, P. H. Stahl and C. G. Wermuth (Eds.), Wiley-VCH, New York, 2002 which are known to the skilled artisan. Pharmaceutically acceptable salts of an acid addition nature are formed when pergolide and any of its intermediates containing a basic functionality are reacted with a pharmaceutically acceptable acid. Pharmaceutically acceptable acids commonly employed to form such acid addition salts include inorganic and organic acids. In one embodiment, a pharmaceutically acceptable salt of pergolide is the mesylate salt.
The formulations employ a solvent system which includes one or more solvents. For the formulations of the invention, the solvents employed in the solvent system include at least one of dimethyl sulfoxide, N-methylpyrrolidone, dimethylf ormamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable Cs-Cio polyglycolized glyceride, and includes suitable mixtures of the above. The solvent system provides the desired solubility of pergolide or a salt thereof, which is 5 mg/ml and higher, and about 25 mg/ml and higher, in the solvent system.
Acidic water is water having a pH of less than 7, which includes a pH of less than 6, less than 5, less than 4, less than 3, and less than 2, as well as having a pH in the range of 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, and 5-6.
WO 2015/195448
PCT/US2015/035237
-5Polyoxyethylene sorbitan monoesters include, for example, polysorbate 80 (polyoxyethylenesorbitol monooleate, Tween®80, BASF Aktiengesellschaft) and Solutol® HS-15 (polyoxyethyleneglycol 660 hydroxystearate, BASF Aktiengesellschaft, CAS Number 70142-34-6).
Cyclodextrins include those described in U.S. Patent Numbers 6,046,177;
5,874,418, 5,376,645, and 5,134,127. Particular cyclodextrins include those marketed under the Kleptose® (such as HPD and HP), and Captisol® (CAS Number 182410-00-0) brands.
Caprylic/capric acid glycerides are those esterification products of caprylic and/or 10 capric acid with glycerol, and are exemplified by those comprising or consisting mainly or essentially of caprylic/capric acid mono- and di-glycerides such as are commercially available under the trade name Imwitor®. A particular caprylic/capric acid glyceride product of this class is Imwitor® 742, which is the esterification product of a mixture of ca. 60 p.p.w. caprylic acid and ca. 40 p.p.w. capric acid with glycerol.
A suitable polyglycolized glyceride is a Cs -Cio polyglycolized glyceride having a
Hydrophilic-Lipophilic-Balance (HLB) of 5 to 16, and in another embodiment having an HLB of about 10 to about 16. Suitable polyglycolized glycerides are exemplified by those marketed under the brand Labrasol®.
2-(2-Ethoxyethoxy)ethanol is available as Transcutol®.
The formulations may employ a volatile liquid in the solvent system. As used herein, the term “volatile liquid” refers to an additional solvent in the solvent system which is more volatile (more readily vaporizable at low temperatures or tends to evaporate more rapidly) than the other solvent(s) in the solvent system. For example, a volatile liquid may be readily vaporizable at low temperatures or tends to evaporate rapidly. The volatile liquid will act as a solubilizer for the pergolide or salt thereof, particularly before administration. The volatile liquid may also act as a penetration enhancer, helping to transition the pergolide or salt thereof and/or the other solvent(s) into the stratum corneum. The volatile liquid will evaporate relatively quickly, leaving a dryfeeling and avoiding dripping. Further, rapid evaporation of the volatile liquid can result in super-saturation of other ingredients of the formulation, avoiding crystallization of the ingredients and increasing the bioavailability of the pergolide or salt thereof. In some embodiments, volatile liquids according to the present invention include safe skin-tolerant
WO 2015/195448
PCT/US2015/035237
-6solvents. In some embodiments, the volatile liquid is a lower alkyl alcohol or a mixture of such alcohols. In some embodiments, the volatile liquid is selected from the group consisting of ethanol, ethyl acetate, isopropanol, acetone, ethyl formate, methanol, methyl acetate, methyl ethyl ketone, pentanol, chloroform, and benzyl alcohol, or a mixture thereof. In other embodiments, the volatile liquid is benzyl alcohol.
The therapeutic amount of the formulations of the invention may vary from one equine to another and can depend upon a number of factors, including the overall physical condition of the equine and the underlying cause of the condition to be treated. In some embodiments, the amount of pergolide, or salt therein, present in the formulation is about
0.05 to about 0.5 milligram per kilogram of equine body weight. In another embodiment, the therapeutically effective amount of pergolide, or salt thereof, present in the formulation is about 0.05 to about 0.3 milligrams per kilogram of equine body weight.
In some embodiments, the single dose transdermal formulation of the formulation comprises between about 0.5 and about 10 mL of a solution of the formulation. In some embodiments, the single dose transdermal formulation of the formulation comprises between about 1 and about 8 mL of a solution of the formulation. In some embodiments, the single dose transdermal formulation of the formulation comprises between about 1 and about 5 mL of a solution of the formulation. In some embodiments, the single dose transdermal formulation of the formulation comprises between about 1 and about 3 mL of a solution of the formulation. In one embodiment, the formulations according to the present invention have a total volume of about 3 ml.
In one embodiment, the formulations according to the present invention have about 10 to about 150 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 25 to about 150 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 25 to about 120 mg of pergolide, or a salt thereof, therein.
In one embodiment, the formulations according to the present invention have about 30 to about 120 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 30 to about 100 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 30 to about 95 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 35 to
WO 2015/195448
PCT/US2015/035237
-7about 95 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 35 to about 80 mg of pergolide, or a salt thereof, therein. In one embodiment, the formulations according to the present invention have about 60 to about 80 mg of pergolide, or a salt thereof, therein.
In some embodiments of the present invention, the formulation is administered for the treatment of Equine Cushing’s Disease. In one embodiment, the formulation is administered for the treatment of Equine Cushing’s Disease as an acute therapy. In another embodiment, the formulation is administered for the treatment of Equine Cushing’s Disease as a chronic therapy. As used herein, “chronic” generally refers to regular administration for an extended period of time. For example, chronic administration encompasses administration that provides sufficient therapeutic blood plasma concentrations on a regular basis. For example, such administration may include administration every other day, once every three, four, five, six, or seven days, for one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve months, or for over a year.
In one embodiment of the present invention, the formulation is contained in a multiple-dose vial prior to administration. The multiple-dose vial containing the formulation of the present invention can be made of glass, plastic, or other material. In one embodiment of the present invention, the formulation is administered as a multiple dose regimen. In one embodiment of the present invention, the formulation is administered as a single dose. In yet another embodiment of the present invention, the formulation is administered as a single unit dose. As used herein, the term “unit dose” is a discrete amount of the formulation comprising a predetermined amount of pergolide or a salt thereof.
In one embodiment, the formulation can be transdermally administered to the equine at a location from which the hair is clipped. In another embodiment, the formulation can be transdermally administered to the equine at a location from which the hair is not clipped. In one embodiment, the formulation can be transdermally administered to the equine at a location at which the skin is cleaned. For example, the skin of the equine can be cleaned with a disinfectant solution. In another embodiment, the formulation can be transdermally administered to the equine at a location at which the skin is not cleaned.
WO 2015/195448
PCT/US2015/035237
-8In one embodiment of the present invention, the formulation is transdermally administered to an equine at a dorsal or dorsum location of the equine. According to the methods of the present invention, the term “dorsal” has its ordinary meaning and as used herein refers to the location on the top of the animal, i.e., along the equine’s back. In one embodiment, the formulation can be administered to the clipped or non-clipped dock (tail root) of the horse. In one embodiment of the present invention, the formulation is transdermally administered to an equine at a ventral location of the equine. According to the methods of the present invention, the term “ventral” has its ordinary meaning and as used herein refers to the direction towards the abdomen of an equine, i.e., along the underside of the equine’s body.
In another embodiment of the present invention, the formulation is transdermally administered to an equine at a location on the foreleg of the equine. According to the methods of the present invention, the term “foreleg” has its ordinary meaning and as used herein refers to any proximal or distal location on either of an equine’s forelegs. In yet another embodiment of the present invention, the formulation is transdermally administered to an equine at a location on the hind leg of the equine. According to the methods of the present invention, the term “hind leg” has its ordinary meaning and as used herein refers to any proximal or distal location on either of an equine’s hind legs.
In one embodiment of the present invention, the formulation is transdermally administered to an equine at a location on the neck of the equine. According to the methods of the present invention, the term “neck” has its ordinary meaning and as used herein refers to any location on either side of the neck. In another embodiment of the present invention, the formulation is transdermally administered to an equine at a location near the mane.
In yet another embodiment of the present invention, the formulation is transdermally administered to an equine at a location underneath the mane. This embodiment may offer further advantages of the present invention because of the mane may protect the administrator (e.g., an owner or caretaker) from the site of administration. Thus, accidental absorption of the formulation by the administrator may be minimized.
In one embodiment of the present invention, the formulation is transdermally administered to an equine at a dorsal location wherein the dorsal location is the upper, mid-cervical region under the mane of the equine. The formulation can be administered
WO 2015/195448
PCT/US2015/035237
-9to the equine in a single line, or in multiple lines, on the dorsal location. In one embodiment, the single line on the dorsal location is approximately four inches long. In another embodiment, the administration may be in a spot. In another embodiment, the administration may be in a line.
The formulations and methods of the present invention include those that also optionally contain one or more other active ingredients, in addition to pergolide or a salt thereof. As used herein, the term “active ingredient” or “therapeutic ingredient” refers to a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates, and solvates of the compound and the prodrugs. Other active ingredients may be combined with pergolide and may be either administered separately or in the same pharmaceutical formulation. The amount of other active ingredients to be given may be readily determined by one skilled in the art based upon therapy with pergolide.
In some embodiments, the single dose transdermal formulation effectively treats a disease in the equine for an effective period of time. In some embodiments, an effective period of time comprises a period of at least 48 hours, a period of at least 72 hours, a period of at least 96 hours (i.e., 4 days), a period of at least 5 days, a period of at least 7 days, a period of at least 10 days, a period of at least 14 days, a period of at least 21 days, a period of at least 28 days, or a period of at least 30 days. In one embodiment, the single dose transdermal formulation is administered once every at least 48 hours. In another embodiment, the single dose transdermal formulation is administered once every at least 72 hours. In yet another embodiment, the single dose transdermal formulation is administered once every at least 96 hours. In another embodiment, the single dose transdermal formulation is administered once every at least 5 days. In another embodiment, the single dose transdermal formulation is administered once every at least 7 days.
In one embodiment, provided is a formulation comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable Cs-Cio polyglycolized glyceride, wherein the solubility of said
WO 2015/195448
PCT/US2015/035237
-10pergolide or salt thereof in said solvent system is 5 mg/ml or higher. In another embodiment, the pergolide or salt thereof is the pergolide free base and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, Solutol® HS15, water with about 40%
Kleptose®, dimethylisosorbide, Imwitor® 742, or Labrasol®. In another embodiment, the pergolide or salt thereof is the pergolide free base and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, or tetrahydrofuran. In another embodiment, the pergolide or salt thereof is the pergolide mesylate and said one or more solvents are selected from dimethyl sulfoxide, N10 methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, Solutol® HS15, or water with about 40% Captisol®. In another embodiment, the pergolide or salt thereof is the pergolide mesylate and said solvent is selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, or water with 40% Captisol®. In another embodiment, the solvent system further comprises at least one volatile liquid which is different than said solvent. In another embodiment, the formulation comprises pergolide mesylate, dimethyl sulfoxide, and polypropylene glycol. In another embodiment, the formulation comprises pergolide mesylate, dimethyl sulfoxide, benzyl alcohol, and polypropylene glycol. In another embodiment, the formulation comprises pergolide free base, dimethyl sulfoxide, benzyl alcohol, and 2-(2-ethoxyethoxy)ethanol. In another embodiment, the formulation comprises pergolide free base, dimethyl sulfoxide, benzyl alcohol, and dimethyl isosorbide.
In one embodiment, provided is a formulation comprising pergolide or salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, or water with about 40% Captisol®, wherein the solubility of said pergolide or salt thereof in said solvent system is about 25 mg/ml or higher. In one embodiment, the solvent system further comprises at least one volatile liquid which is different than said solvent.
In one embodiment, the at least one volatile liquid is selected from the group consisting of ethanol, ethyl acetate, isopropanol, acetone, ethyl formate, methanol, methyl acetate, methyl ethyl ketone, pentanol, chloroform, and benzyl alcohol. In one embodiment, the
WO 2015/195448
PCT/US2015/035237
-11pergolide or salt thereof is pergolide free base, and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, or tetrahydrofuran.
In one embodiment, the formulation comprises pergolide free base, dimethyl sulfoxide, benzyl alcohol, and 2-(2-ethoxyethoxy)ethanol. In one embodiment, the formulation comprises pergolide free base, dimethyl sulfoxide, benzyl alcohol, and dimethyl isosorbide. In one embodiment, the pergolide or salt thereof is pergolide mesylate, and said solvent is selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, or water with about 40% Captisol®. In one embodiment, the formulation comprises pergolide mesylate, dimethyl sulfoxide, benzyl alcohol, and polypropylene glycol. In one embodiment, the formulation comprises pergolide mesylate, dimethyl sulfoxide, and polypropylene glycol. In one embodiment, the formulation comprises pergolide mesylate in about 40-50% dimethyl sulfoxide, about 20-25% benzyl alcohol, and about 25-35% polypropylene glycol. In one embodiment, the formulation comprises pergolide mesylate in about 40-50% dimethyl sulfoxide and about
50-60% polypropylene glycol. In one embodiment, the formulation comprises pergolide free base in about 40-50% dimethyl sulfoxide, about 20-30% benzyl alcohol, and about 20-30% 2-(2-ethoxyethoxy)ethanol. In one embodiment, the formulation comprises pergolide free base in about 40-50% dimethyl sulfoxide, about 30-40 % benzyl alcohol, and about 10-20% dimethyl isosorbide. In one embodiment, the formulation comprises about 120 mg of pergolide mesylate in about 40-50% dimethyl sulfoxide, about 20-25% benzyl alcohol, and about 25-35% polypropylene glycol. In one embodiment, the formulation comprises about 120 mg pergolide mesylate in about 40-50% dimethyl sulfoxide and about 50-60% polypropylene glycol. In one embodiment, the formulation comprises about 30 mg pergolide free base in about 40-50% dimethyl sulfoxide, about
20-30% benzyl alcohol, and about 20-30% 2-(2-ethoxyethoxy)ethanol. In one embodiment, the formulation comprises about 30 mg pergolide free base in about 40-50% dimethyl sulfoxide, about 30-40% benzyl alcohol, and about 10-20% dimethyl isosorbide. In one embodiment, the formulation comprises about 120 mg of pergolide mesylate in about 46.7% dimethyl sulfoxide, about 22.6% benzyl alcohol, and about 30.7% polypropylene glycol. In one embodiment, the formulation comprises about 120 mg pergolide mesylate in about 46.7% dimethyl sulfoxide and about 53% polypropylene glycol. In one embodiment, the formulation comprises about 30 mg pergolide free base
WO 2015/195448
PCT/US2015/035237
-12in about 46.7% dimethyl sulfoxide, about 27.7% benzyl alcohol, and about 25.6% 2-(2ethoxyethoxy)ethanol. In one embodiment, the formulation comprises about 30 mg pergolide free base in about 47.6% dimethyl sulfoxide, about 35.9 % benzyl alcohol, and about 15.4% dimethyl isosorbide.
In one embodiment, the formulation is in a single unit dosage transdermal form.
In one embodiment, the formulation comprises about 10 to about 150 mg of the pergolide or salt thereof. In one embodiment, the formulation is characterized in that said pergolide or salt thereof is provided in an amount of about 0.05 to about 0.50 mg/kg of the weight of an equine. In one embodiment, the formulation is characterized in that said pergolide or salt thereof is provided in an amount of about 0.05 to about 0.30 mg/kg of the weight of an equine. In one embodiment, the formulation is adapted to be administered once every other day to an equine. In one embodiment, the formulation is adapted to be administered once every 3, 4, 5, 6, or 7 days to an equine. In one embodiment, the formulation is adapted to be administered once every 7 days to an equine. In one embodiment, the formulation volume is about 1 to about 5 ml. In one embodiment, the formulation volume is about 3 ml.
The following clauses illustrate embodiments of the invention.
1. A formulation comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N20 methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable C8-C10 polyglycolized glyceride, wherein the solubility of said pergolide or salt thereof in said solvent system is 5 mg/ml or higher.
2. The formulation of clause 1, wherein said pergolide or salt thereof is the pergolide free base and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, Solutol® HS15, water with about 40% Kleptose®, dimethylisosorbide, Imwitor® 742, or Labrasol®
3. The formulation of clause 1, wherein said pergolide or salt thereof is the pergolide free base and said solvent is selected from dimethyl sulfoxide, Nmethylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water,
WO 2015/195448
PCT/US2015/035237
-13Solutol® HS15, water with about 40% Kleptose®, dimethylisosorbide, Imwitor® 742, or
Labrasol®
4. The formulation of any of clauses 1-3, wherein said pergolide or salt thereof is the pergolide free base and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, or tetrahydrofuran.
5. The formulation of clause 1, wherein said pergolide or salt thereof is the pergolide mesylate and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, Solutol® HS15, or water with about 40%
Captisol®.
6. The formulation of clause 1, wherein said pergolide or salt thereof is the pergolide mesylate and said solvent is selected from dimethyl sulfoxide, Nmethylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, Solutol® HS15, or water with about 40% Captisol®.
7. The formulation of clause 1, 5 or 6, wherein said pergolide or salt thereof is the pergolide mesylate and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, or water with 40% Captisol®.
8. The formulation of clause 1, 5, 6 or 7 comprising pergolide mesylate, dimethyl sulfoxide, and polypropylene glycol.
9. The formulation of any of clauses 1-8, wherein said solvent system further comprises at least one volatile liquid which is different than said solvent.
10. The formulation of claim 9, wherein said at least one volatile liquid is selected from the group consisting of ethanol, ethyl acetate, isopropanol, acetone, ethyl formate, methanol, methyl acetate, methyl ethyl ketone, pentanol, chloroform, and benzyl alcohol, and mixtures thereof.
11. The formulation of clause 10, comprising pergolide mesylate, dimethyl sulfoxide, benzyl alcohol, and polypropylene glycol.
12. The formulation of clause 10, comprising pergolide free base, dimethyl sulfoxide, benzyl alcohol, and 2-(2-ethoxyethoxy)ethanol.
WO 2015/195448
PCT/US2015/035237
-1413. The formulation of clause 10, comprising pergolide free base, dimethyl sulfoxide, benzyl alcohol, and dimethyl isosorbide.
14. A formulation comprising pergolide or salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N5 methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, or water with about 40% Captisol®, wherein the solubility of said pergolide or salt thereof in said solvent system is about 25 mg/ml or higher.
15. The formulation of clause 14, wherein said solvent system further comprises at least one volatile liquid which is different than said solvent.
16. The formulation of clause 15, wherein said at least one volatile liquid is selected from the group consisting of ethanol, ethyl acetate, isopropanol, acetone, ethyl formate, methanol, methyl acetate, methyl ethyl ketone, pentanol, chloroform, and benzyl alcohol, and mixtures thereof.
17. The formulation of clause 14, wherein said pergolide or salt thereof is pergolide free base, and said one or more solvents are selected from dimethyl sulfoxide,
N-methylpyrrolidone, dimethylformamide, or tetrahydrofuran.
18. The formulation of clause 14, wherein said pergolide or salt thereof is pergolide free base, and said solvent is selected from dimethyl sulfoxide, Nmethylpyrrolidone, dimethylformamide, or tetrahydrofuran.
19. The formulation of clause 14 or 17, comprising pergolide free base and dimethyl sulfoxide and further comprising benzyl alcohol, and 2-(2ethoxyethoxy)ethanol.
20. The formulation of clause 14 or 17, comprising pergolide free baseand dimethyl sulfoxide and further comprising benzyl alcohol, and dimethyl isosorbide.
21. The formulation of clause 14, wherein said pergolide or salt thereof is pergolide mesylate.
22. The formulation of clause 14 or 21, comprising pergolide mesylate, dimethyl sulfoxide and benzyl alcohol, and further comprising polypropylene glycol.
23. The formulation of clause 14 or 21, comprising pergolide mesylate and dimethyl sulfoxide, and further polypropylene glycol.
WO 2015/195448
PCT/US2015/035237
-1524. The formulation of clause 14, comprising pergolide mesylate in about 40-50% dimethyl sulfoxide and about 20-25% benzyl alcohol, and further comprising about 25-35% polypropylene glycol.
25. The formulation of clause 14, comprising pergolide mesylate in about 40-50% dimethyl sulfoxide and further comprising about 50-60% polypropylene glycol.
26. The formulation of clause 14, comprising pergolide free base in about 40-50% dimethyl sulfoxide and about 20-30% benzyl alcohol, and further comprising about 20-30% 2-(2-ethoxyethoxy)ethanol.
27. The formulation of clause 14, comprising pergolide free base in about 40-50% dimethyl sulfoxide and about 30-40 % benzyl alcohol, and further comprising about 10-20% dimethyl isosorbide.
28. The formulation of clause 14, comprising about 120 mg of pergolide mesylate in about 40-50% dimethyl sulfoxide and about 20-25% benzyl alcohol, and further comprising about 25-35% polypropylene glycol.
29. The formulation of clause 14, comprising about 120 mg pergolide mesylate in about 40-50% dimethyl sulfoxide and further comprising about 50-60% polypropylene glycol.
30. The formulation of clause 14, comprising about 30 mg pergolide 20 free base in about 40-50% dimethyl sulfoxide, and about 20-30% benzyl alcohol, and further comprising about 20-30% 2-(2-ethoxyethoxy)ethanol.
31. The formulation of clause 14, comprising about 30 mg pergolide free base in about 40-50% dimethyl sulfoxide, and about 30-40% benzyl alcohol, and further comprising about 10-20% dimethyl isosorbide.
32. The formulation of clause 14, comprising about 120 mg of pergolide mesylate in about 46.7% dimethyl sulfoxide, and about 22.6% benzyl alcohol, and further comprising about 30.7% polypropylene glycol.
33. The formulation of clause 14, comprising about 120 mg pergolide mesylate in about 46.7% dimethyl sulfoxide and further comprising about 53% polypropylene glycol.
WO 2015/195448
PCT/US2015/035237
-1634. The formulation of clause 14, comprising about 30 mg pergolide free base in about 46.7% dimethyl sulfoxide, and about 27.7% benzyl alcohol, and further comprising about 25.6% 2-(2-ethoxyethoxy)ethanol.
35. The formulation of clause 14, comprising about 30 mg pergolide free 5 base in about 47.6% dimethyl sulfoxide, and about 35.9 % benzyl alcohol, and about
15.4% dimethyl isosorbide.
36. The formulation of any of clauses 1-35, wherein said formulation is in a single unit dosage transdermal form.
37. The formulation of clause 36, comprising about 10 to about 150 mg 10 of the pergolide or salt thereof.
38. The formulation of clause 36 or 37, wherein said formulation is characterized in that said pergolide or salt thereof is provided in an amount of about 0.05 to about 0.50 mg/kg of the weight of an equine.
39. The formulation of 38, wherein said formulation is characterized in 15 that said pergolide or salt thereof is provided in an amount of about 0.05 to about 0.30 mg/kg of the weight of an equine.
40. The formulation of any of clauses 36-39, wherein said formulation is adapted to be administered once every other day to an equine.
41. The formulation of any of clauses 36-39, wherein said formulation 20 is adapted to be administered once every 3, 4, 5, 6, or 7 days to an equine.
42. The formulation of any of clauses 36-39, wherein said formulation is adapted to be administered once every 7 days to an equine.
43. The formulation of any of clauses 36-39, wherein said formulation volume is about 1 to about 5 ml.
44. The formulation of clause 43, wherein said formulation volume is about 3 ml.
45. A method for treating a disease in an equine comprising transdermally administering to the equine in need thereof a formulation of any of clauses 1-44.
46. The method of clause 45, wherein the disease is Equine Cushing’s
Disease.
WO 2015/195448
PCT/US2015/035237
-1747. The method of clause 45 or 46, wherein the formulation is administered as an acute therapy.
48. The method of clause 45 or 46, wherein the formulation is administered as a chronic therapy.
49. The method of any of clauses 45-48, wherein the formulation is applied to a dorsal location of the equine.
50. The method of clause 49, wherein the dorsal location is a midcervical region under the mane of the equine.
51. The method of any of clauses 45-48, wherein the formulation is 10 applied to a location on the neck of the equine.
52. The method of any of clauses 45-48, wherein the formulation is applied to a ventral location of the equine.
53. The method of any of clauses 45-48, wherein the formulation is applied to a location on the foreleg of the equine.
54. The method of any of clauses 45-48, wherein the formulation is applied to a location on the hindleg of the equine.
55. The method of any of clauses 45-48, wherein the formulation is applied to the dock (tail root) of the equine.
56. The method of any of clauses 45-55, wherein the pergolide or salt 20 thereof is provided at a dose of about 25 to about 150 mg.
57. The method of any of clauses 45-56, wherein the pergolide or salt thereof is provided at a dose of about 0.05 to about 0.30 mg/kg of the equine.
58. The method of any one of clauses 45-57, wherein the formulation is administered with one or more other therapeutic ingredients.
59. A formulation of any of clauses 1-44 for use in therapy.
60. A formulation of any of clauses 1-44 for use in treating a disease in an equine.
61. The formulation for use according to clause 60, wherein the disease is Equine Cushing’s Disease.
62. The formulation for use according to clause 60 or 61, wherein the formulation is administered as an acute therapy.
WO 2015/195448
PCT/US2015/035237
-1863. The formulation for use according to clause 60 or 61, wherein the formulation is administered as a chronic therapy.
64. The formulation for use according to any of clauses 60-63, wherein the formulation is applied to a dorsal location of the equine.
65. The formulation for use according to clause 64, wherein the dorsal location is a mid-cervical region under the mane of the equine.
66. The formulation for use according to any of clauses 60-63, wherein the formulation is applied to a location on the neck of the equine.
67. The formulation for use according to any of clauses 60-63, wherein 10 the formulation is applied to a ventral location of the equine.
68. The formulation for use according to any of clauses 60-63, wherein the formulation is applied to a location on the foreleg of the equine.
69. The formulation for use according to any of clauses 60-63, wherein the formulation is applied to a location on the hindleg of the equine.
70. The formulation for use according to any of clauses 60-63, wherein the formulation is applied to the dock (tail root) of the equine.
71. The formulation for use according to any of clauses 60-70, wherein the pergolide or salt thereof is provided at a dose of about 25 to about 150 mg.
72. The formulation for use according to any of clauses 60-70, wherein 20 the pergolide or salt thereof is provided at a dose of about 0.05 to about 0.30 mg/kg of the equine.
73. The formulation for use according to any one of clauses 60-72, wherein the formulation is administered with one or more other therapeutic ingredients.
74. The use of a formulation of any of clauses 1-44 for the manufacture 25 of a medicament for the treatment of Equine Cushing’s disease in a equine.
Study 1: Comparative Study of a Transdermal Pergolide Mesylate Formulation
Administered to Equines 30
A formulation is formulated to comprise about 1.25% (w/v) (12.5 mg/ml) of pergolide mesylate, about 5% (w/v) of octyl salicylate, and about 94% (w/v) of methanol.
WO 2015/195448
PCT/US2015/035237
-19The formulation is transdermally administered to four horses weighing between 391 and 452 kg at a dose of about 10 mg. The formulation is transdermally administered to the skin of the equine in the upper, mid-cervical region under the mane. Following administration to the equines, the plasma concentration of pergolide is assayed at intervals of approximately 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144 and 168 hours post-administration. The lower limit of quantification for the plasma concentration of pergolide in equines is about 50 pg/mL. Following administration, plasma concentrations of pergolide are detectable, but are not quantifiable in all horses.
Study 2: Study of Four Transdermal Pergolide Free Base Formulations Administered to
Equines
This study is conducted to characterize the pharmacokinetics of pergolide free base when transdermally applied in four different transdermal formulations to the clipped and cleaned forelegs of 12 mature horses weighing between 456.5 and 576.5 kg. The formulations/treatments are:
1) 6 ml containing 36 mg of pergolide free base in padimate O in ethanol 5:95, pH adjusted to 3 with phosphoric acid (comparative formulation);
2) 6 ml containing 36 mg of pergolide free base in 10% dimethyl sulfoxide in 20 ethanol, pH adjusted to 3 with phosphoric acid;
3) 4 ml containing 60 mg of pergolide free base in N-methyl pyrrolidone; and
4) 2 ml containing 80 mg of pergolide free base in dimethyl sulfoxide/ammonium phosphate buffer 90:10.
On Day 0 the formulations are administered to to three horses per treatment group. 25 Doses are divided equally between the left and right upper lateral forelegs which have been clipped and clean approximately 10 minutes prior to administration. Blood samples are collected into a sodium heparin and a K2EDTA tube one hour prior to administration, at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-administration. The lower limit of quantification for the plasma concentration of pergolide is about 5 pg/ml.
Pergolide is quantifiable in all horses through 120 hours post dose. Average Cmax ranges from 632 ng/ml for Treatment 3 to 2867 ng/ml for Treatment 4. Maximum concentrations are highly variable, with CV’s greater than 40% for each treatment group. The average half-life ranges from 31.5 hours for Treatment 4 to 56.2 hours for Treatment
WO 2015/195448
PCT/US2015/035237
-203. Despite a large difference in the amount of drug applied by the different treatments,
AUC(o-iast) remains relatively consistent, from 20,433 pg/ml*hr for Treatment 3 to 31,235 pg/ml*hr for Treatment 4.
Study 3: Study of Pergolide Mesylate Administered Orally, Subcutaneously, and
Transdermally to Equines
This study is conducted to characterize the pharmacokinetics of pergolide mesylate when administered orally, subcutaneously, or transdermally to five horses weighing between 510 to 551 kg. The three treatments are:
1) Subcutaneous injection(SC): 1 ml of a 2 mg/ml solution in 20% Captisol® in water (2 mg dose of pergolide mesylate);
2) Oral (PO): Prascend® tablet (1 mg dose of pergolide mesylate); and
3) Transdermal (TD): 4 ml of 15 mg/ml solution in N-methyl pyrrolidone (NMP) (2 ml per foreleg/60 mg dose of pergolide mesylate).
Treatment 1 is injected in the axillary area. Treatment 3 is divided equally between the left and right upper lateral forelegs which have been clipped prior to treatment and cleaned with alcohol approximately 10 minutes prior to treatment. Blood samples are collected prior to treatment and at 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96 120, 144, and 168 (treatment 3 only) hours after dosing for determination of plasma pergolide and prolactin concentrations. The lower limit of quantification for the plasma concentration of pergolide is about 5 pg/ml.
Pergolide is quantifiable in all horses through 48 hours after treatment 1, through
12 hours after treatment 2, and through 144 hours after treatment 3. The average Cmax is quite consistent among the treatment groups ranging from 673 to 892 pg/ml. The average AUC(0-iast) is markedly higher for the treatment 3 group compared to treatments 1 and 2 (12,149 vs 5,162 and 1,065 pg/ml*hr, respectively). Similarly, the average half-life of treatment 3 is longer than those observed for treatments 1 and 2 (29 vs 13 and 6 hours, respectively). The average Tmax is 1.1 hours for treatment 1, 0.35 hours for treatment 2, and 2.6 hours for treatment 3.
In comparison, in Study 2 pergolide free base is applied in the same formulation and similar dose as treatment 3 of Study 3. The Cmax observed in Study 2 is 632 pg/ml,
WO 2015/195448
PCT/US2015/035237
-21similar to that for the present study’s mesylate form in NMP. The average half-life is longer (56.2 hours) and the average AUC(0.iast) is higher (20,433 pg/ml*hr) for the free base form in NMP compared to mesylate.
Study 4: Study of an Oral Pergolide Tablet Administered to Equines
In this comparative study, 1 mg pergolide mesylate tablets (Prascend® tablet) are given once a day orally for seven days to horses, for a total administration of 7 mg per horse. Blood samples are obtained one hour prior to dosing and at 15 min, 30 min, and 1,
2, 4, 6, 8, 12, and 23 hours after the initial dose. For days 2-6, blood samples are collected at 30 min, 2, 8, and 23 hours after each dose. For the final dose (dose 7), blood samples are obtained at 15 min, 30 min, 1, 2, 4, 6, 8, 12, 23, 36, 48, and 72 hours after the final dose. The lower limit of quantification for the plasma concentration of pergolide is about 5 pg/ml.
The oral administration produces an average AUCo-ies of 10,702 pg/mL (+ 4108
Standard Deviation (SD)) over the course of treatment. Over all seven doses, Tmax ranges from 0.25 hr - 1 hr, with the average value being 0.5 hrs post dose, and the half-life after the seventh dose ranges from 2.7 hrs to 13.29 hrs, with the average half-life being 8.35 hrs. The average Cmax for the first dose is 389.17 (+ 167.09) and for the seventh dose is
305.67 (+87.03), demonstrating little if any accumulation occurs over the dosing period.
Fig. 1 sets out results of the study.
Study 5: Study of Pergolide Mesylate and Free Base Administered Transdermally to
Equines
This study is conducted to determine the pharmacokinetics of four different transdermal pergolide formulations when administered to the clipped dock (tail root) of 16 horses, weighing 425 to 562 kgs. The four treatment groups are:
1) 120 mg pergolide mesylate in 46.7% dimethyl sulfoxide/22.6% benzyl alcohol/30.7% polypropylene glycol (concentration of 30 mg/ml; equivalent to a dose of 92 mg of pergolide free base);
2) 120 mg pergolide mesylate in 46.7% dimethyl sulfoxide/53.0% polypropylene glycol (concentration of 30 mg/ml; equivalent to a dose of 92 mg of pergolide free base);
WO 2015/195448
PCT/US2015/035237
-223) 30 mg pergolide free base in 46.7% dimethyl sulfoxide/27.7% benzyl alcohol/25.6% Transcutol® (concentration of 8 mg/ml); and
4) 30 mg pergolide free base in 47.6% dimethyl sulfoxide/35.9% benzyl alcohol/15.4% dimethyl isosorbide (concentration of 8 mg/ml).
Blood samples for determination of pergolide plasma concentrations are obtained within one hour prior to dosing and at 30 minutes, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96 120, 144, and 168 hours after dosing.
Pergolide is quantifiable in all horses through 168 hours following administration of treatments 1 and 3 . Treatment 2 has quantifiable pergolide levels in all horses through
144 hours. Treatment 4 has quantifiable pergolide levels in all horses through 96 hours.
Treatment 1 has the following average ( ± SD) pharmacokinetic parameters: a half-life of 57.15 hours (± 28.54), a Tmax of 4 hours (± 1.63), a Cmax of 352.25 (± 123.94), an AUC (o-iast) of 10,746.80 hour*pg/ml (± 5368.81), and an AUC(o-inf) of 11,773.7 hour*pg/ml (± 5876.04).
Treatment 2 has the following average ( ± SD) pharmacokinetic parameters: a half-life of 50.27 hours (± 5.17), a Tmax of 5 hours (± 2.58), a Cmax of 183.53 (± 72.97), an AUC(o-iast) of 6897.80 hour*pg/ml (± 2754.93), and an AUC(o-mf) of 7647.02 hour*pg/ml (± 3006.84).
Treatment 3 has the following average ( ± SD) pharmacokinetic parameters: a half-life of 75.40 hours (± 30.52), a of 1.5 hours (± 0.58), a Cmax of 231.00 (±
111.36), an AUC(o-iast) of 5189.74 hour*pg/ml (± 1220.16), and an AUC(o-inf) of 6038.93 hour*pg/ml (± 1423.58).
Treatment 4 has the following average ( ± SD) pharmacokinetic parameters: a half-life of 35.01 hours (± 11.06), a Tmax of 2.5 hours (± 1.73), a Cmax of 267.53 (±
154.06), an AUC(o-iast) of 4303.77 hour*pg/ml (± 2120.35), and an AUC(o-inf) of 4599.74 hour*pg/ml (± 2089.17).
Fig. 2 sets out results of the study.
H:\rbr\Interwoven\NRPortbl\DCC\RBR\12172693_l.docx-25/11/2016
2015277554 25 Nov 2016
-23 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word comprise, and variations such as comprises and comprising, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
EDITORIAL NOTE
Application No. 2015277554
Please Note: Description ends on page 23 and claims commence on a second page 23.
H:\rbr\Interwoven\N RPortbl\DCC\RBR\l6427242_l.docx-7/02/20l8
2015277554 07 Feb 2018

Claims (2)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1/2
Figure 1 (liu/Gd) uogejjuaauoo eiusqd
WO 2015/195448
PCT/US2015/035237
1. A method for treating Equine Cushing's Disease in an equine comprising transdermally administering to an equine in need thereof a transdermal non-patch
5 formulation, the formulation comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable C8-C10 polyglycolized
10 glyceride, wherein the pergolide or salt thereof is comprised in said solvent system at a solubility of 5 mg/ml or higher.
2. The method of claim 1, wherein said pergolide or salt thereof is the pergolide free base and said one or more solvents are selected from dimethyl sulfoxide, N15 methylpyrrolidone, dimethylformamide, tetrahydro furan, benzyl alcohol, acidic water, polyoxyethyleneglycol 660 hydroxystearate, water with about 40% cyclodextrin, dimethylisosorbide, the esterification product of a mixture of ca. 60 p.p.w. caprylic acid and ca. 40 p.p.w. capric acid with glycerol, or a suitable C8-C10 polyglycolized glyceride.
20
3. The method of claim 1, wherein said pergolide or salt thereof is the pergolide mesylate and said one or more solvents are selected from dimethyl sulfoxide, Nmethylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polypropylene glycol, methanol, polyoxyethyleneglycol 660 hydroxystearate, or water with about 40% of CAS Number 182410-00-0.
4. The method of claim 1, comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, or water with about 40% of CAS Number 182410-00-0, wherein the pergolide or salt thereof is comprised in said solvent
30 system at a solubility of about 25 mg/ml or higher.
H:\rbr\Intcrwovcn\N RPortbl\DCC\RBR\l6427242_l.docx-7/02/20l8
2015277554 07 Feb 2018
-245. The method of any one of claims 1 to 4, wherein said solvent system further comprises at least one volatile liquid which is different than said solvent.
6. The method of claim 5, wherein said at least one volatile liquid is selected from the 5 group consisting of ethanol, ethyl acetate, isopropanol, acetone, ethyl formate, methanol, methyl acetate, methyl ethyl ketone, pentanol, chloroform, and benzyl alcohol, and mixtures thereof.
7. The method of claim 4, comprising pergolide mesylate, and dimethyl sulfoxide, 10 and further comprising polypropylene glycol.
8. Use of a transdermal non-patch formulation in the preparation of a medicament for treating Equine Cushing’s Disease, the formulation comprising pergolide or a salt thereof, and a solvent system comprising one or more solvents selected from dimethyl sulfoxide,
15 N-methylpyrrolidone, dimethylformamide, tetrahydro furan, benzyl alcohol, acidic water, polypropylene glycol, methanol, a polyoxyethylene sorbitan monoester, water with about 40% of a cyclodextrin, dimethyl isosorbide, a caprylic/capric acid glyceride, or a suitable C8-C10 polyglycolized glyceride, wherein the pergolide or salt thereof is comprised in said solvent system at a solubility of 5 mg/ml or higher.
9. The use of claim 8, wherein said pergolide or salt thereof is the pergolide free base and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, acidic water, polyoxyethyleneglycol 660 hydroxystearate, water with about 40% cyclodextrin, dimethylisosorbide, the
25 esterification product of a mixture of ca. 60 p.p.w. caprylic acid and ca. 40 p.p.w. capric acid with glycerol, or a suitable C8-C10 polyglycolized glyceride.
10. The use of claim 8, wherein said pergolide or salt thereof is the pergolide mesylate and said one or more solvents are selected from dimethyl sulfoxide, N-methylpyrrolidone,
30 dimethylformamide, tetrahydro furan, benzyl alcohol, acidic water, polypropylene glycol,
H:\rbr\Interwoven\N RPortbl\DCC\RBR\l6427242_l.docx-7/02/20l8
2015277554 07 Feb 2018
-25 methanol, polyoxyethyleneglycol 660 hydroxystearate, or water with about 40% of CAS Number 182410-00-0.
11. The use of claim 8, comprising pergolide or a salt thereof, and a solvent system 5 comprising one or more solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, dimethylformamide, tetrahydrofuran, benzyl alcohol, or water with about 40% of CAS
Number 182410-00-0, wherein the pergolide or salt thereof comprised in said solvent system at a solubility of about 25 mg/ml or higher.
10
12. The use of any one of claims 8 to 11, wherein said solvent system further comprises at least one volatile liquid which is different than said solvent.
13. The use of claim 12, wherein said at least one volatile liquid is selected from the group consisting of ethanol, ethyl acetate, isopropanol, acetone, ethyl formate, methanol,
15 methyl acetate, methyl ethyl ketone, pentanol, chloroform, and benzyl alcohol, and mixtures thereof.
14. The use of claim 11, comprising pergolide mesylate, and dimethyl sulfoxide, and further comprising polypropylene glycol.
WO 2015/195448
PCT/US2015/035237
2/2
Figure 2
O '43 tn c
E <
g{
O
Q to o
CL
O
I (iui/6d) uohbirwouoo eiuseid
1000
AU2015277554A 2014-06-18 2015-06-11 Transdermal formulations of pergolide and uses thereof Active AU2015277554C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013819P 2014-06-18 2014-06-18
US62/013,819 2014-06-18
PCT/US2015/035237 WO2015195448A1 (en) 2014-06-18 2015-06-11 Transdermal formulations of pergolide and uses thereof

Publications (3)

Publication Number Publication Date
AU2015277554A1 AU2015277554A1 (en) 2016-11-03
AU2015277554B2 true AU2015277554B2 (en) 2018-03-01
AU2015277554C1 AU2015277554C1 (en) 2018-05-31

Family

ID=53484178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015277554A Active AU2015277554C1 (en) 2014-06-18 2015-06-11 Transdermal formulations of pergolide and uses thereof

Country Status (9)

Country Link
US (1) US9987267B2 (en)
EP (1) EP3166642B1 (en)
JP (1) JP6276429B2 (en)
AU (1) AU2015277554C1 (en)
CA (1) CA2946434C (en)
ES (1) ES2807211T3 (en)
NZ (1) NZ725354A (en)
PL (1) PL3166642T3 (en)
WO (1) WO2015195448A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110384656A (en) * 2018-04-19 2019-10-29 上海现代药物制剂工程研究中心有限公司 Edaravone nasal administration composition and its nasal administration formulation preparation method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120995A1 (en) * 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DE19821788C1 (en) 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system (TTS) containing pergolide
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
JP2005506297A (en) * 2001-03-30 2005-03-03 エラン ファーマシューティカルズ インコーポレイテッド Pergolide transdermal delivery
CA2682323A1 (en) * 2007-04-02 2008-10-09 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120995A1 (en) * 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INNERA M. ET AL., "Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses", VETERINARY DERMATOLOGY, (2013), vol. 24, pages 212 - e47 *

Also Published As

Publication number Publication date
EP3166642B1 (en) 2020-06-03
NZ725354A (en) 2018-05-25
AU2015277554C1 (en) 2018-05-31
PL3166642T3 (en) 2020-11-30
US20170095468A1 (en) 2017-04-06
ES2807211T3 (en) 2021-02-22
US9987267B2 (en) 2018-06-05
EP3166642A1 (en) 2017-05-17
JP6276429B2 (en) 2018-02-07
CA2946434C (en) 2021-07-06
AU2015277554A1 (en) 2016-11-03
JP2017517536A (en) 2017-06-29
CA2946434A1 (en) 2015-12-23
WO2015195448A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
JP4996472B2 (en) Transmucosal animal composition containing detomidine
EP2906213B1 (en) A veterinary method of alleviating noise aversion
KR20190096376A (en) Dexmedetomidine or medemidine for use in the treatment of segregation anxiety in dogs
US8748467B2 (en) Topical formulation
AU2015277554B2 (en) Transdermal formulations of pergolide and uses thereof
WO2017025912A1 (en) Aripiprazole compositions and methods for its transdermal delivery

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 FEB 2018

PC1 Assignment before grant (sect. 113)

Owner name: ELANCO US INC.

Free format text: FORMER APPLICANT(S): ELI LILLY AND COMPANY

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 FEB 2018

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AUDEVARD

Free format text: FORMER OWNER(S): ELANCO US INC.